RU2011103459A - Фармацевтическая композиция с гликозаминогликанами и ее применение при лечении хронических язв - Google Patents

Фармацевтическая композиция с гликозаминогликанами и ее применение при лечении хронических язв Download PDF

Info

Publication number
RU2011103459A
RU2011103459A RU2011103459/15A RU2011103459A RU2011103459A RU 2011103459 A RU2011103459 A RU 2011103459A RU 2011103459/15 A RU2011103459/15 A RU 2011103459/15A RU 2011103459 A RU2011103459 A RU 2011103459A RU 2011103459 A RU2011103459 A RU 2011103459A
Authority
RU
Russia
Prior art keywords
composition according
heparin
pharmaceutical composition
plasma
life
Prior art date
Application number
RU2011103459/15A
Other languages
English (en)
Russian (ru)
Inventor
ЭНСИНА Иван ЛОПЕС-БЕЛЬМОНТЕ (ES)
ЭНСИНА Иван ЛОПЕС-БЕЛЬМОНТЕ
МАЙОРДОМО Мария де Лос Анхелес КАНАЛЕС (ES)
МАЙОРДОМО Мария де Лос Анхелес КАНАЛЕС
МИРАНДА Элена СЕБАДЕРА (ES)
МИРАНДА Элена СЕБАДЕРА
Original Assignee
Лабораториос Фармасеутикос Рови, С.А. (Es)
Лабораториос Фармасеутикос Рови, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лабораториос Фармасеутикос Рови, С.А. (Es), Лабораториос Фармасеутикос Рови, С.А. filed Critical Лабораториос Фармасеутикос Рови, С.А. (Es)
Publication of RU2011103459A publication Critical patent/RU2011103459A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2011103459/15A 2008-07-01 2009-06-30 Фармацевтическая композиция с гликозаминогликанами и ее применение при лечении хронических язв RU2011103459A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200802002 2008-07-01
ES200802002A ES2340902B1 (es) 2008-07-01 2008-07-01 Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.

Publications (1)

Publication Number Publication Date
RU2011103459A true RU2011103459A (ru) 2012-08-10

Family

ID=41319881

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011103459/15A RU2011103459A (ru) 2008-07-01 2009-06-30 Фармацевтическая композиция с гликозаминогликанами и ее применение при лечении хронических язв

Country Status (15)

Country Link
US (2) US20110201572A1 (enExample)
EP (1) EP2308497B1 (enExample)
JP (1) JP2011526608A (enExample)
CN (1) CN102176915A (enExample)
AU (1) AU2009265623B2 (enExample)
BR (1) BRPI0913839A2 (enExample)
CA (1) CA2766483C (enExample)
CY (1) CY1115780T1 (enExample)
DK (1) DK2308497T3 (enExample)
ES (2) ES2340902B1 (enExample)
MX (1) MX2010014552A (enExample)
PL (1) PL2308497T3 (enExample)
PT (1) PT2308497E (enExample)
RU (1) RU2011103459A (enExample)
WO (3) WO2010000905A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357601B1 (es) * 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
JP2012245943A (ja) * 2011-05-31 2012-12-13 Hitachi Automotive Systems Ltd 制御装置
JP5942133B2 (ja) * 2012-09-11 2016-06-29 学校法人関西文理総合学園 蛍光プローブ及びこれを用いた酵素活性検出方法
AU2016235662B2 (en) * 2015-03-20 2020-07-30 Aarhus Universitet Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders
EP3273239A1 (en) * 2016-07-19 2018-01-24 Laboratorios Farmacéuticos Rovi, S.A. Procedure of analysis of glycosaminoglycans, heparins and their derivatives by nuclear magnetic resonance
CN111194220B (zh) * 2017-09-05 2024-06-18 黄玲惠 用于治疗缺血的肝素组合物
CN114072430B (zh) * 2020-04-27 2023-07-28 罗威制药股份有限公司 低分子量肝素获取程序以及由此获得的低分子量肝素

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004A (en) * 1849-01-09 chinnqck
CH636888A5 (fr) * 1977-08-08 1983-06-30 Choay Sa Heparines purifiees et leur preparation.
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
FR2482611B1 (fr) * 1980-05-14 1986-03-07 Pharmindustrie Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
AU1173599A (en) * 1997-11-20 1999-06-15 Ikuo Yamashina Low-molecular heparin modification and remedy for skin ulcer
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
EP1357931A2 (en) 2001-01-08 2003-11-05 Human Genome Sciences, Inc. Keratinocyte growth factor-2
CU23043A1 (es) 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
BR0309707A (pt) 2002-05-02 2005-02-09 Pfizer Prod Inc Tratamento de diabetes e complicações diabéticas com inibidores nhe-1
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético

Also Published As

Publication number Publication date
WO2010000906A1 (es) 2010-01-07
CA2766483C (en) 2017-01-17
DK2308497T3 (da) 2014-07-14
CN102176915A (zh) 2011-09-07
ES2476966T3 (es) 2014-07-15
CA2766483A1 (en) 2010-01-07
JP2011526608A (ja) 2011-10-13
US9211305B2 (en) 2015-12-15
EP2308497A1 (en) 2011-04-13
WO2010000905A1 (es) 2010-01-07
AU2009265623B2 (en) 2014-11-20
EP2308497B1 (en) 2014-04-16
WO2010000904A1 (es) 2010-01-07
MX2010014552A (es) 2011-04-26
ES2340902B1 (es) 2011-05-03
PL2308497T3 (pl) 2014-10-31
US20110201572A1 (en) 2011-08-18
ES2340902A1 (es) 2010-06-10
BRPI0913839A2 (pt) 2015-10-20
CY1115780T1 (el) 2017-01-25
AU2009265623A1 (en) 2010-01-07
US20140066402A1 (en) 2014-03-06
PT2308497E (pt) 2014-07-24

Similar Documents

Publication Publication Date Title
RU2011103459A (ru) Фармацевтическая композиция с гликозаминогликанами и ее применение при лечении хронических язв
CY1113183T1 (el) Χρηση νατριουριτικου πεπτιδιου για θεραπεια καρδιακης ανεπαρκειας
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
JP2011526608A5 (enExample)
EA201100007A1 (ru) Производные хиноксалиндиона
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
MX384378B (es) Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca.
JP2012517449A5 (enExample)
RU2011113762A (ru) Способы применения композиций с замедленным высвобождением аминопиридина
JP2018172440A5 (enExample)
CU20160088A7 (es) Piperidinil-tetrahidroquinolinas sustituidas
AR052565A1 (es) Prevencion y tratamiento de trastornos tromboembolicos
PH12014501579A1 (en) Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers
WO2011039780A3 (en) Topical formulation for diabetic foot ulcers
EA201100916A1 (ru) Комбинация инсулина с триазиновыми производными и их применение для лечения диабета
AR061352A1 (es) El uso de timosina alfa 1 para preparar un medicamento destinado al tratamiento del melanoma maligno de estadio iv
AR046969A1 (es) Composicion enteral para la cicatrizacion de heridas
PH12013500711A1 (en) Acylbenzene derivative
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
WO2010062205A4 (en) Indication of use of erdosteine as antidote in a large number of intoxications, especially in heavy metals like lead or mercury, and paracetamol
DE602004018352D1 (de) Therapeutische anwendungen für c-peptid
EA200970877A1 (ru) Композиция, пригодная для предупреждения диабета 2 типа и его осложнений у пациентов с предиабетом с резистентностью к инсулину
JP2015522000A5 (enExample)
RU2011108631A (ru) Способ профилактики несостоятельности кишечного анастомоза